ASH 2017 | AML highlights from ASH 2017
Charles Craddock
• 9 Dec 2017
There was a long period of time without new acute myeloid leukemia (AML) treatments, but now there are a number of promising therapies on the horizon. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the novel AML therapies presented at the meeting. Prof. Craddock highlights the promising clinical data for CPX-351, a liposomal mixture of cytarabine and danorubicin. He also emphasizes data for IDH-1/2 inhibitors, translational studies investigating the clonal structure of patients in complete remission and allogeneic stem cell transplantation.
